22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › JANUX THERAPEUTICS INC. › 2024-2025

JANUX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and JANUX THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 232Asset managers, any item
  • 1,844Fund votes
  • June 11, 2025Meeting date

Results at a glance

Meeting of June 11, 2025: 5 items on JANUX THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (22.4% against).

Notable dissent: 2 directors (19.1%, 17.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13D, 19.9%, as of March 10, 2025) · Nantahala Capital (13F, 1.4%, as of September 30, 2026)

Explore JANUX THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by JANUX THERAPEUTICS INC.

These tallies are JANUX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

JANUX THERAPEUTICS INC. — official shareholder meeting results, meeting held June 11, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: David Campbell, Ph.D. 44,740,538---- 9,631,8291,866,944 82%Elected—
Elect Director: Ron Barrett, Ph.D. 44,005,362---- 10,367,0051,866,944 81%Elected—
Elect Director: Winston Kung 42,187,543---- 12,184,8241,866,944 78%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 56,152,99027,38158,941 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 53,205,9891,150,94715,431 --1,866,944 98%Approved—

Source: JANUX THERAPEUTICS INC., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.

How asset managers voted at the JANUX THERAPEUTICS INC. 2024-2025 meeting

232 asset managers disclosed a vote on at least one JANUX THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of JANUX THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: David Campbell, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 44,740,538WITHHELD: 9,631,829
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Campbell, Ph.D.”): 44,740,538 for, 9,631,829 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 14,627,558 for, 1,840,349 withheld.

FOR
FOR: 14,627,558WITHHOLD: 1,840,349
Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,262,8890 00For
Vanguard2,207,7270 00For
JANUS INVESTMENT FUND00 01,328,416Withhold
BlackRock1,319,8200 00For
T. Rowe Price1,066,4060 00For
FRANKLIN STRATEGIC SERIES445,2520 00For
Putnam333,5520 00For
Charles Schwab276,7240 00For
State Street258,4620 0337For
Columbia Threadneedle238,4250 00For
Aberdeen224,7880 00For
Invesco203,5480 00For
Victory Capital00 0180,836Withhold
TIAA121,0360 00For
Equitable97,8600 00For
Bridge Builder Trust6,1320 084,722Mixed
Delaware/Macquarie00 076,601Withhold
Russell Investments60,9140 00For
QUANTITATIVE MASTER SERIES LLC53,8170 00For
Hartford51,2440 00For
Lincoln Financial31,6770 016,621Mixed
JPMorgan48,2620 00For
Tema ETF Trust46,4530 00For
Northern Trust41,4960 00For
John Hancock24,7960 011,657Mixed

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Ron Barrett, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 44,005,362WITHHELD: 10,367,005
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Barrett, Ph.D.”): 44,005,362 for, 10,367,005 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 14,255,451 for, 2,212,456 withheld.

FOR
FOR: 14,255,451WITHHOLD: 2,212,456
Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,262,8890 00For
Vanguard2,207,7270 00For
JANUS INVESTMENT FUND00 01,328,416Withhold
BlackRock1,319,8200 00For
T. Rowe Price1,066,4060 00For
FRANKLIN STRATEGIC SERIES445,2520 00For
Putnam333,5520 00For
Charles Schwab276,7240 00For
State Street258,4620 0337For
Columbia Threadneedle238,4250 00For
Aberdeen00 0224,788Withhold
Invesco203,5480 00For
Victory Capital00 0180,836Withhold
TIAA121,0360 00For
Equitable57,7830 040,077Mixed
Bridge Builder Trust6,1320 084,722Mixed
Delaware/Macquarie00 076,601Withhold
Russell Investments60,9140 00For
QUANTITATIVE MASTER SERIES LLC53,8170 00For
Hartford51,2440 00For
Lincoln Financial31,6770 016,621Mixed
JPMorgan48,2620 00For
Tema ETF Trust46,4530 00For
Northern Trust00 041,496Withhold
John Hancock24,7960 011,657Mixed

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Winston Kung

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD
FOR: 42,187,543WITHHELD: 12,184,824
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Winston Kung”): 42,187,543 for, 12,184,824 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 13,961,474 for, 2,506,433 withheld.

FORWITHHOLD
FOR: 13,961,474WITHHOLD: 2,506,433
Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,262,8890 00For
Vanguard2,207,7270 00For
JANUS INVESTMENT FUND00 01,328,416Withhold
BlackRock1,319,8200 00For
T. Rowe Price1,066,4060 00For
FRANKLIN STRATEGIC SERIES445,2520 00For
Putnam333,5520 00For
Charles Schwab00 0276,724Withhold
State Street258,4620 0337For
Columbia Threadneedle238,4250 00For
Aberdeen00 0224,788Withhold
Invesco203,5480 00For
Victory Capital00 0180,836Withhold
TIAA121,0360 00For
Equitable57,7830 040,077Mixed
Bridge Builder Trust6,1320 084,722Mixed
Delaware/Macquarie00 076,601Withhold
Russell Investments00 060,914Withhold
QUANTITATIVE MASTER SERIES LLC53,8170 00For
Hartford51,2440 00For
Lincoln Financial31,6770 016,621Mixed
JPMorgan48,2620 00For
Tema ETF Trust46,4530 00For
Northern Trust41,4960 00For
John Hancock24,7960 011,657Mixed

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 53,205,989AGAINST: 1,150,947
Details: description as filed, official tally, votes by 232 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.

JANUX THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 53,205,989 for, 1,150,947 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 71 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclos” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,262,8890 00For
Vanguard2,207,7270 00For
JANUS INVESTMENT FUND1,328,4160 00For
BlackRock1,319,8200 00For
T. Rowe Price1,066,4060 00For
FRANKLIN STRATEGIC SERIES445,2520 00For
Putnam333,5520 00For
Charles Schwab276,7240 00For
State Street258,78415 00For
Columbia Threadneedle238,4250 00For
Aberdeen0224,788 00Against
Invesco0203,548 00Against
Victory Capital180,8360 00For
TIAA121,0360 00For
Equitable97,8600 00For
Bridge Builder Trust90,8540 00For
Delaware/Macquarie76,6010 00For
Russell Investments60,9140 00For
QUANTITATIVE MASTER SERIES LLC53,8170 00For
Hartford51,2440 00For
Lincoln Financial48,2980 00For
JPMorgan48,2620 00For
Tema ETF Trust46,4530 00For
Northern Trust41,4960 00For
John Hancock36,4530 00For

Fund voting reports, all 71 managers: 16,008,184 for, 457,264 against, 2,459 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 181 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclos” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RA CAPITAL MANAGEMENT, L.P.10,287,7460 00For
Fidelity8,858,7630 00For
Janus Henderson2,962,1924,657 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.2,899,4000 00For
Paradigm Biocapital Advisors LP2,554,3350 00For
Woodline Partners LP1,530,8330 00For
EcoR1 Capital, LLC1,469,8180 00For
Logos Global Management LP1,450,0000 00For
T. Rowe Price1,439,1750 00For
BlackRock1,110,2240 00For
Cormorant Asset Management, LP898,0760 00For
State Street846,84612,494 00For
FRANKLIN ADVISERS INC813,1750 00For
GEODE CAPITAL MANAGEMENT, LLC790,4610 00For
Point72779,4660 00For
ORBIMED ADVISORS LLC720,0000 00For
PICTET ASSET MANAGEMENT SA592,5860 00For
MPM BioImpact LLC419,2350 00For
Putnam365,7440 00For
Alyeska Investment Group, L.P.343,0910 00For
Citadel338,6750 00For
Victory Capital286,0020 00For
Wellington278,2650 00For
Charles Schwab276,7240 00For
Ensign Peak Advisors, Inc268,0950 00For

Institutional-manager reports, all 181 managers: 45,065,206 for, 856,880 against, 4,905 not voted, 11,262 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 223 asset managers

Description as filed by funds: Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 71 asset managers voting on “Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compens” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
Vanguard00 00--
JANUS INVESTMENT FUND00 00--
BlackRock00 00--
T. Rowe Price00 00--
FRANKLIN STRATEGIC SERIES00 00--
Putnam00 00--
Charles Schwab00 00--
State Street00 00--
Columbia Threadneedle00 00--
Aberdeen00 00--
Invesco00 00--
Victory Capital00 00--
TIAA00 00--
Equitable00 00--
Bridge Builder Trust00 00--
Delaware/Macquarie00 00--
Russell Investments00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
Hartford00 00--
Lincoln Financial16,6210 00For
JPMorgan00 00--
Tema ETF Trust00 00--
Northern Trust00 00--
John Hancock00 00--

Fund voting reports, all 71 managers: 16,621 for, 2,459 abstained, 16,448,827 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 174 asset managers voting on “Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compens” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RA CAPITAL MANAGEMENT, L.P.00 00--
Fidelity00 00--
Janus Henderson00 00--
Paradigm Biocapital Advisors LP00 00--
Woodline Partners LP00 00--
EcoR1 Capital, LLC00 00--
Logos Global Management LP00 00--
T. Rowe Price00 00--
BlackRock00 00--
Cormorant Asset Management, LP00 00--
State Street00 00--
FRANKLIN ADVISERS INC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Point7200 00--
ORBIMED ADVISORS LLC00 00--
PICTET ASSET MANAGEMENT SA00 00--
MPM BioImpact LLC00 00--
Putnam00 00--
Alyeska Investment Group, L.P.00 00--
Citadel00 00--
Victory Capital00 00--
Wellington00 00--
Charles Schwab00 00Not Voted
Ensign Peak Advisors, Inc00 00--
Invesco00 00--

Institutional-manager reports, all 174 managers: 366,585 for, 172 against, 38,100 abstained, 4,905 not voted, 42,217,226 1 year, 268,826 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 56,152,990AGAINST: 27,381

Prior year: 100.0% for (June 26, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

JANUX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 56,152,990 for, 27,381 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 16,465,169 for, 279 against, 2,459 abstained.

FOR
FOR: 16,465,169AGAINST: 279ABSTAIN: 2,459
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDE” at JANUX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,262,8890 00For
Vanguard2,207,7270 00For
JANUS INVESTMENT FUND1,328,4160 00For
BlackRock1,319,8200 00For
T. Rowe Price1,066,4060 00For
FRANKLIN STRATEGIC SERIES445,2520 00For
Putnam333,5520 00For
Charles Schwab276,7240 00For
State Street258,7990 00For
Columbia Threadneedle238,4250 00For
Aberdeen224,7880 00For
Invesco203,5480 00For
Victory Capital180,8360 00For
TIAA121,0360 00For
Equitable97,8600 00For
Bridge Builder Trust90,8540 00For
Delaware/Macquarie76,6010 00For
Russell Investments60,9140 00For
QUANTITATIVE MASTER SERIES LLC53,8170 00For
Hartford51,2440 00For
Lincoln Financial48,2980 00For
JPMorgan48,2620 00For
Tema ETF Trust46,4530 00For
Northern Trust41,4960 00For
John Hancock36,4530 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Largest JANUX THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,168,490 shares outstanding at the time of that meeting.

Fund voting reports: top JANUX THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 12.27%
2Vanguard 3.73%
3JANUS INVESTMENT FUND 2.25%
4BlackRock 2.23%
5T. Rowe Price 1.80%
6FRANKLIN STRATEGIC SERIES 0.75%
7Putnam 0.56%
8Charles Schwab 0.47%
9State Street 0.44%
10Columbia Threadneedle 0.40%
Institutional-manager reports: top JANUX THERAPEUTICS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1RA CAPITAL MANAGEMENT, L.P. 17.39%
2Fidelity 14.97%
3Janus Henderson 5.01%
4ADAGE CAPITAL PARTNERS GP, L.L.C. 4.90%
5Paradigm Biocapital Advisors LP 4.32%
6Woodline Partners LP 2.59%
7EcoR1 Capital, LLC 2.48%
8Logos Global Management LP 2.45%
9T. Rowe Price 2.43%
10BlackRock 1.88%

Reported JANUX THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

JANUX THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with RA Capital Healthcare Fund, L.P.12,175,165 —Proxy statement (DEF 14A), proxy filed April 25, 2025
RA Capital Management, L.P.11,971,377 —Schedule 13D, filed March 10, 2025
FMR (Fidelity)8,884,072 —Form 13F, quarter ended March 31, 2025
FMR LLC7,824,674 —Proxy statement (DEF 14A), proxy filed April 25, 2025
JANUS HENDERSON GROUP PLC4,196,409 —Schedule 13G, filed May 15, 2026
Entities affiliated with Janus Henderson Group plc3,562,402 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Entities affiliated with Paradigm BioCapital Advisors GP LLC3,515,986 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Prosight Management, LP3,150,970 —Schedule 13G, filed February 6, 2026
Entities affiliated with Adage Capital Management, L.P.3,061,750 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Bregua Corporation2,999,990 —Proxy statement (DEF 14A), proxy filed April 25, 2025

Percentages above are of 59,168,490 shares outstanding, as reported by JANUX THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At JANUX THERAPEUTICS INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 232 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,844 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers… — JANUX THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: JANUX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from JANUX THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

JANUX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “JANUX THERAPEUTICS (JANX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/janux-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.